Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + PCb-EC vs PCb as Neoadjuvant Therapy for TNBC
NCT07256964Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of toripalimab in triple-negative breast cancer (TNBC), sponsored by Henan Cancer Hospital. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07256964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07256964.